Form 4: Apellis Officer James Chopas Receives RSU Grant

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, was granted 16,150 Restricted Stock Units vesting over four years.

Summary

• James Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), received a grant of 16,150 shares of Common Stock.
• The transaction date for this grant was January 28, 2026.
• The shares were granted as a Restricted Stock Unit (RSU) award with a price of $0.
• These RSUs will vest 25% annually over four years from the grant date, contingent on continued service.
• Following this transaction, James Chopas beneficially owns 65,955 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices and a commitment to retaining key personnel, which generally supports stable corporate governance.

Positives

• Increased alignment of management's interests with shareholders through an equity grant.
• The grant of 16,150 Restricted Stock Units (RSUs) to a key executive demonstrates continued commitment to the company.
• The four-year vesting schedule encourages long-term retention and performance from the VP/Chief Accounting Officer.

Negatives

• No direct negatives are apparent from this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The Restricted Stock Units granted to James Chopas are scheduled to vest 25% annually over four years from the grant date of January 28, 2026, subject to his continued service with Apellis Pharmaceuticals.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align the interests of executives with those of shareholders by tying a portion of their compensation to the company's long-term stock performance and executive retention. This particular grant to the VP/Chief Accounting Officer is a routine disclosure of such compensation.

Comparison to Industry Standards

• Equity compensation for executives, particularly through RSU grants with multi-year vesting schedules, is a common practice across the pharmaceutical and biotech sectors.
• Companies like Pfizer, Johnson & Johnson, and Moderna frequently utilize similar structures to incentivize and retain key personnel.
• The 25% annual vesting over four years is a standard industry practice, comparable to grants seen at many peer companies, ensuring long-term commitment.

Related Party Transactions

• The grant of Restricted Stock Units to James Chopas, a VP/Chief Accounting Officer, constitutes a related party transaction as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: The grant aligns the executive's long-term interests with shareholder value creation, potentially leading to more stable management. It also represents a dilution of existing shares over time as RSUs vest, though this is typically factored into compensation planning.
• Employees: This grant reinforces the company's compensation structure for key executives, which can influence overall employee morale and retention strategies.

Next Steps

• The Restricted Stock Units will vest 25% annually over the next four years, contingent on James Chopas's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice. It does not contain information that would significantly alter the fundamental outlook or valuation of Apellis Pharmaceuticals, Inc. Therefore, it is unlikely to be a primary driver for a "buy" or "sell" decision, supporting a "hold" recommendation based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, James Chopas, Equity Grant